Leukogene Therapeutics receives funding to develop compound for resistant multiple myeloma
(Medical University of South Carolina) Leukogene Therapeutics, Inc., a start-up company founded by a Medical University of South Carolina researcher, will optimize a promising compound for combating resistance in the treatment of multiple myeloma and other cancers with funding from an STTR grant.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Cancer | Cancer & Oncology | Funding | Grants | International Medicine & Public Health | Myeloma